 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Maraviroc (Selzentry, Celsentri)
READ FIRST:
- Maraviroc Overview: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From The Body PRO
Overview
- A Clinical Overview of Maraviroc (Selzentry, Celsentri) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo - FDA Approves First CCR5 Inhibitor Maraviroc (August 7, 2007)
The U.S. Food and Drug Administration (FDA) on Monday approved Pfizer's antiretroviral drug maraviroc, which belongs to a new class of antiretrovirals that could provide an alternative to HIV-positive people who have developed resistance to multiple drugs, the Los Angeles Times reports. FDA gave expedited approval of maraviroc for use in combination with other antiretrovirals. FDA approved maraviroc on the condition that the drug's label include a black-box warning -- the "strongest possible advisory" -- according to the Times. The drug also will have a warning about an increased risk of heart attack. Helmut Albrecht, director of the University of South Carolina's Division of Infectious Diseases who was not involved with any maraviroc trials, said he was "cautiously optimistic" about the drug. He added, "It's so completely new that it is sort of difficult to see how well this is going to do over time." The last new class of antiretrovirals was approved by FDA in 2003 (Los Angeles Times, 8/7).
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Approval of Maraviroc (August 6, 2007)
From U.S. Food and Drug Administration - Prescribing Information for Maraviroc (Selzentry, Celsentri) (PDF) (August 2007)
From Pfizer, Inc.
Research & News
- IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide (January 30, 2008)
From International Partnership for Microbicides - ICAAC: Maraviroc Failures Associated With Shifts From R5-Tropic to Mixed or X4-Tropic HIV (September 20, 2007)
From aidsmap.com - IAS: Maraviroc Produces Best Results When Combined With Another Active Drug (August 14, 2007)
From aidsmap.com - Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - European Advisory Panel Recommends Approval of Pfizer's Antiretroviral Maraviroc, Company Says (July 23, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Held Up in U.S., First CCR5 Inhibitor Nears Approval in Europe (July 20, 2007)
From aidsmap.com - Pfizer Advises Maraviroc Dose Increase if Combined With Etravirine (July 20, 2007)
From aidsmap.com - FDA Issues Approvable Letter for Pfizer's Antiretroviral Maraviroc (June 21, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
From Treatment Action Group - FDA Panel Recommends Agency Approve Pfizer's Antiretroviral Maraviroc (April 25, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - CROI: Maraviroc Shows Potent Effect in Highly Treatment-Experienced (February 28, 2007)
From aidsmap.com - Maraviroc + OBT Potent in Treatment-Experienced HIV-Infected Patients: An Interview With Roy Gulick, M.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - United States: Pfizer to Expand Access to HIV Drug (December 5, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - HIV Antiretroviral Agents in Development: Entry Inhibitors (March 30, 2006)
From The Body - Once-Daily Arm in Maraviroc Treatment-Naive Study Terminated (January 30, 2006)
From aidsmap.com - Case Study of a Patient With Serious Hepatotoxicity in Maraviroc 2b/3 Trial Reported at Targeting HIV Entry -- 1st International Workshop (December 3, 2005)
To read PDF, click here
From Pfizer, Inc. - The CCR5 Antagonist UK-427,857 (Maraviroc) Shows Strong Activity in Phase 1/2a Monotherapy Studies (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Entry Inhibitors in Development (July 2004)
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here
In Project Inform Perspective, from Project Inform
  |
  |